14.56

0.07% -0.010

After Hours: 14.61 0.05 +0.34%

Phathom Pharmaceuticals Inc (PHAT)

Overview News Price History Option Chain Financials Discussions Forecast

Phathom Pharmaceuticals Inc stock is traded at $14.56, with a volume of 1.24M. It is down -0.07% in the last 24 hours and down -0.41% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Previous Close:

$14.57

Open:

$15.22

24h Volume:

1.24M

Relative Volume:

1.20

Market Cap:

$1.04B

Revenue:

$114.04M

Net Income/Loss:

$-330.15M

P/E Ratio:

-3.0782

EPS:

-4.73

Net Cash Flow:

$-274.85M

1W Performance:

-0.14%

1M Performance:

-0.41%

6M Performance:

+45.16%

1Y Performance:

+82.34%

1-Day Range:

$14.51

$16.45

1-Week Range:

$14.12

$16.45

52-Week Range:

$2.21

$16.45

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name

Phathom Pharmaceuticals Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(877) 742-8466

Address

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Employee

427

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHAT Phathom Pharmaceuticals Inc	14.56	1.04B	114.04M	-330.15M	-274.85M	-4.73
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Initiated	Raymond James	Strong Buy
Dec-09-25	Initiated	Barclays	Equal Weight
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight
May-03-24	Initiated	Stifel	Buy
Jan-05-24	Reiterated	Needham	Buy
Aug-09-23	Initiated	H.C. Wainwright	Buy
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral
Feb-17-21	Initiated	BMO Capital Markets	Outperform
Feb-02-21	Initiated	Guggenheim	Buy
Jun-26-20	Downgrade	Goldman	Neutral → Sell
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Goldman	Neutral
Nov-19-19	Initiated	Jefferies	Buy
Nov-19-19	Initiated	Needham	Buy

View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

Dec 13, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month HighWhat's Next? - MarketBeat

Dec 13, 2025

683 Capital Management LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat

Dec 13, 2025

Dec 12, 2025

Phathom Pharmaceuticals stock hits 52-week high at $16.27 By Investing.com - Investing.com India

Dec 12, 2025

Dec 11, 2025

Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating - Investing.com Canada

Dec 11, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat

Dec 11, 2025

(PHAT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com

Dec 11, 2025

Dec 10, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 10, 2025

Dec 09, 2025

Barclays Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Equal-Weight Recommendation - Nasdaq

Dec 09, 2025

Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target - marketscreener.com

Dec 09, 2025

Dec 06, 2025

Is WPIL Limited Still a Good Stock to Buy After Recent Earnings - earlytimes.in

Dec 06, 2025

Nov 30, 2025

Responsive Playbooks and the PHAT Inflection - news.stocktradersdaily.com

Nov 30, 2025

Nov 29, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year HighWhat's Next? - MarketBeat

Nov 29, 2025

Nov 28, 2025

Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD By Investing.com - Investing.com Nigeria

Nov 28, 2025

Nov 27, 2025

Is Phathom Pharmaceuticals Inc a good long term investmentIPO Market Watch & Budget Friendly Capital Growth - earlytimes.in

Nov 27, 2025

How Phathom Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Earnings & Accurate Intraday Trading Signals - moha.gov.vn

Nov 27, 2025

Nov 24, 2025

Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk - Traders Union

Nov 24, 2025

Nov 21, 2025